Compare AbbVie Inc (ABBV) vs Opendoor Technologies Inc (OPEN) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Opendoor Technologies (OPEN) trades at $4.79, down 2.24% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $1.30 billion on $4.37 billion revenue in 2025, with a negative net income margin of -35.25%. Recent news highlights a new CEO, a shift to the Opendoor 2.0 model, and the closure of India operations to focus on AI-driven efficiencies.

The outlook remains challenging with persistent losses and a highly leveraged balance sheet, though cost discipline and AI integration offer potential for margin improvement. Key risks include housing market volatility and high debt levels. Analyst consensus is cautious with 65.39% hold ratings, reflecting uncertainty around the path to profitability.